8-K: COMPASS PATHWAYS Achieves Phase 3 Primary Endpoint for COMP360 in TRD

Compass Pathways plc announced highly statistically significant positive topline results from its second pivotal Phase 3 COMP006 trial for COMP360 psilocybin in treatment-resistant depression, alongside consistent safety data.

Summary

• Successful achievement of the primary endpoint in the Phase 3 COMP006 trial for COMP360 in treatment-resistant depression (TRD).
• COMP006 trial demonstrated a highly statistically significant reduction in symptom severity (p<0.001) and a clinically meaningful difference of -3.8 points in MADRS scores at Week 6 for COMP360 25 mg versus 1 mg.
• COMP005 trial (previously disclosed in June 2025) showed a highly statistically significant mean treatment difference of -3.6 points (p<0.001) in MADRS scores at Week 6 for a single dose of COMP360 25 mg versus placebo.
• Rapid onset of action was observed in both trials, with statistical significance from the day following administration, maintained at all measured timepoints through Week 6 in the 25 mg arm.
• Durability was demonstrated in COMP005, where 25% of participants with a clinically meaningful reduction in MADRS maintained the treatment effect for at least 26 weeks after just one or two doses.
• Over 40% of COMP005 participants who achieved a clinically meaningful reduction but had not remitted by Week 6 went into remission after a second dose in Part B.
• COMP360 exhibited a generally well-tolerated and safe profile across both trials, with most treatment-emergent adverse events (TEAEs) being mild or moderate in severity and resolving within 24 hours.
• Common TEAEs included headache, nausea, visual hallucination, and anxiety.
• Treatment-emergent serious adverse events (SAEs) occurred in 5% of participants in the COMP005 25 mg arm (Part A and B) and 2% in the COMP006 25 mg arm (Part A).
• The rate for SAE suicidal ideation was less than 1% across both trials; one event of SAE suicidal behavior occurred in the 1 mg arm in COMP006.
• The company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss a rolling submission and review for a New Drug Application (NDA), with completion expected in Q4 2026.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, given the successful achievement of primary endpoints in two pivotal Phase 3 trials, demonstrating rapid onset and durable efficacy for a significant unmet medical need in TRD, coupled with a clear path to NDA submission.

Positives

• Highly statistically significant primary endpoint achievement in both pivotal Phase 3 trials (COMP005 and COMP006) for COMP360 in TRD (p<0.001 for both).
• Demonstrated rapid onset of action, with statistical significance observed from the day following administration and maintained through Week 6 in both trials.
• Sustained durability of treatment effect, with 25% of COMP005 participants maintaining a clinically meaningful reduction in MADRS through at least Week 26 after one or two doses.
• Potential for deeper treatment effect with a second administration, as over 40% of COMP005 participants not remitted by Week 6 achieved remission after a second dose.
• Generally well-tolerated and safe profile, with the majority of TEAEs resolving within 24 hours and no new safety signals identified.
• COMP360 has Breakthrough Therapy designation from the FDA, potentially expediting regulatory review.
• Company is planning for a rolling NDA submission and review, with expected completion in Q4 2026, indicating a clear and accelerated path to market.

Negatives

• Treatment-emergent adverse events (TEAEs) such as headache, nausea, visual hallucination, and anxiety were common, although mostly mild/moderate and resolving quickly.
• Serious adverse events (SAEs) occurred in 5% of participants in COMP005 (25mg arm, Part A and B) and 2% in COMP006 (25mg arm, Part A).
• One event of SAE suicidal behavior occurred in the 1 mg arm in COMP006, though the overall rate for SAE suicidal ideation was less than 1% across both trials.

Risks

• Uncertainties associated with clinical development, which is a lengthy and expensive process with uncertain outcomes, potentially leading to delays, termination, or higher costs for clinical trials.
• The full results and safety data from the Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date.
• Acceleration strategies for NDA submission may not be successful.
• The FDA may ultimately disagree with the company's proposal for a rolling NDA submission and may not permit the use of the rolling review process.
• Efforts to obtain marketing approval from the FDA or other regulatory authorities for investigational COMP360 psilocybin treatment may be unsuccessful.
• Need for substantial additional funding to achieve business goals; inability to obtain this funding when needed and on acceptable terms could force delays, limits, or termination of clinical trials.
• Efforts to commercialize and obtain coverage and reimbursement for COMP360, if approved, may be unsuccessful.
• The risk that strategic collaborations will not continue or will not be successful.
• Ability to retain key personnel.

Future Outlook

The company plans to meet with the U.S. Food and Drug Administration (FDA) as soon as possible to discuss a rolling submission and review for COMP360 psilocybin treatment in TRD. They expect to complete a New Drug Application (NDA) submission in Q4 2026. The emerging clinical profile of COMP360 is seen as redefining rapidity and durability for TRD patients, supporting a potentially highly compelling, novel paradigm.

Management Comments

• "The emerging clinical profile of COMP360 is redefining rapidity and durability for TRD patients."
• "The robust benefit/risk profile of COMP360 supports a potentially highly compelling, novel paradigm for patients and providers where effectiveness may be determined almost immediately after a single treatment."
• "Patients with a clinically meaningful reduction in MADRS from the first treatment have shown the potential for sustained benefit through at least 26 weeks, after one or two doses."
• "These results increase our conviction in the potential importance of this treatment for TRD patients."
• "We are planning to meet as soon as possible with the FDA to discuss a rolling submission and review, and expect to complete an NDA submission in Q4."

Industry Context

StockSavvy.ai notes that the successful Phase 3 results for COMP360 position Compass Pathways as a potential leader in the nascent psychedelic-assisted therapy space, specifically for Treatment-Resistant Depression (TRD). The demonstrated rapid onset and sustained durability with a single or two doses could offer a significant advantage over existing TRD treatments, which often require daily dosing or have less pronounced long-term efficacy. The market for TRD is substantial, with over 4 million U.S. adults experiencing it annually and only a few approved medicines, highlighting a significant unmet need that COMP360 aims to address.

Comparison to Industry Standards

• COMP360's rapid onset (statistically significant from Day 2) and sustained durability (at least 26 weeks after 1-2 doses for responders) are presented as highly differentiated compared to traditional antidepressants and Spravato (esketamine).
• Traditional antidepressants typically have an onset of 2-8 weeks and require daily dosing, whereas COMP360 shows effect from Day 2 with single or two doses.
• Spravato (Janssen's esketamine nasal spray) showed a -4.0 MADRS difference (p=0.02) at Day 28 in the TRANSFORM 2 trial, with an induction phase of twice-weekly dosing for a month, followed by maintenance. COMP360 achieved a -3.6 (COMP005) and -3.8 (COMP006) MADRS difference at Week 6, with a single or two doses.
• The filing highlights that "No approved drug offers clinically meaningful efficacy with both rapid onset and sustained durability with a single treatment," suggesting COMP360 could set a new standard in TRD treatment.
• The TRD market has limited options, with Spravato being a primary treatment used by fewer than 100,000 patients annually, indicating a large underserved population that COMP360 could target.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial results, de-risking the development pathway and increasing the likelihood of regulatory approval and commercialization, potentially leading to increased share price.
• Patients (TRD): Significant positive impact by offering a potentially highly effective treatment with rapid onset and durable effects for a chronic and refractory condition with limited current options.
• Healthcare Providers: Provides a novel treatment paradigm that could redefine care for TRD patients, offering a new tool for managing difficult-to-treat depression.

Next Steps

• Meet with the U.S. Food and Drug Administration (FDA) to discuss a rolling submission and review for COMP360.
• Complete a New Drug Application (NDA) submission in Q4 2026.
• Release 26-week data (Part B) from the COMP006 trial in early Q3 2026.
• Transition from a clinical-stage to a commercial-stage organization and effectively launch a commercial product, if regulatory approval is obtained.

Key Dates

Recommendation

The successful achievement of primary endpoints in two pivotal Phase 3 trials for COMP360 in Treatment-Resistant Depression (TRD), demonstrating highly statistically significant efficacy, rapid onset, and durable response, significantly de-risks the company's lead asset. The clear path towards a rolling NDA submission in Q4 2026, coupled with Breakthrough Therapy designation, indicates strong potential for regulatory approval and subsequent commercialization in a market with substantial unmet need. While risks associated with clinical development and commercialization remain, these positive topline results represent a major milestone that warrants a "strong buy" recommendation for long-term investors.

Keywords

COMPASS PATHWAYS, CMPS, COMP360, Psilocybin, Treatment-Resistant Depression, TRD, Phase 3 Clinical Trials, COMP005, COMP006, FDA, NDA Submission, Mental Health, Breakthrough Therapy, Clinical Development, Biotechnology, Pharmaceuticals